Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney Cancers

Recruiting

• Conditions: Kidney Cancer

• Registration Number: NCT04946266
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

An exploratory analysis of the expression of MFI2-AS1 will be performed at the plasma level with the objective of comparing this expression with tumor tissue. The objective would be to be able to use long non-coding RNA as a biomarker for diagnosis before tissue analysis and for patient follow-up. In addition, correlations will be made between tumor expression of MFI2-AS1 and genetic and immune alterations in tumors in order to better clarify the link between the expression of this long non-coding RNA and the characteristics of the tumor and of the tumor. tumor microenvironment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-06-22
• Study First Submitted QC: 2021-06-22
• Study First Posted: 2021-06-30
• Status Verified: 2021-12
• Study Start: 2021-12-01
• Primary Completion: 2021-12-01
• Last Update Submitted: 2021-12-13
• Last Update Posted: 2022-01-05
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 260

Inclusion Criteria

• Adult patient
• Localized kidney tumors> T1a
• Patient having signed an informed consent
• Patient affiliated to a health insurance plan
• Subject having signed a consent form to participate in research and the constitution of a collection and genetic analyzes

Exclusion Criteria

• Metastatic carcinoma from the outset
• Contraindication to performing a TAP CT with injection of contrast product
• Inability to provide informed information about the subject (subject in an emergency situation, difficulties in understanding, etc.)
• Subject under legal protection
• Subject under tutorship or curatorship
• Pregnancy
• Feeding with milk

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Expression of MFI2-AS1	36 month	To assess the link between tumor expression of MFI2-AS1 in patients with localized clear cell kidney carcinoma and the occurrence of relapse

Trial Locations

Locations (1)

Les Hôpitaux Universitaires de Strasbourg; 🇫🇷 Strasbourg, France